Abcam, ab264035, Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Monoclonal Amyloid-beta precursor protein antibody. Carrier free. Suitable for Dot, WB, I-ELISA and reacts with Synthetic peptide, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:IBR-10-2-3,
Isotype:IgG1,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, I-ELISA, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab244035
is a carrier free version of
ab264034
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Pyroglutamate beta amyloid also known by its abbreviation pGlu-Aβ is a modified form of beta amyloid that plays a significant role in the pathology of Alzheimer's disease. This peptide is approximately 40-42 amino acids in length contributing to its molecular mass range of 4 to 5 kDa. Pyroglutamate beta amyloid is generated through a post-translational modification where glutamate residues on beta amyloid undergo cyclization. This modification imparts stability and resistance to degradation causing it to accumulate in the brain. Researchers find pyroglutamate beta amyloid mainly in the neurons and plaques of the brains of Alzheimer’s patients.
Biological function summary
Pyroglutamate beta amyloid affects neuronal function by increasing the aggregation propensity of beta amyloid. It enhances the toxic effects on synapses and neurons disrupting communication and leading to synaptic dysfunction. Pyroglutamate-modified amyloid beta is a component of the amyloid plaque complex which includes other amyloid peptides and metal ions. The presence of pGlu-Aβ in these plaques enhances their stability and neurotoxicity accelerating neuronal degradation and loss of cognitive functions.
Pathways
Modified pyroglutamate beta amyloid involves itself in amyloidogenic pathways that include processes such as the beta-secretase and gamma-secretase pathways. These pathways lead to production and modification of amyloid beta peptide initiating plaque formation in the brain. The interaction of pyroglutamate beta amyloid with tau protein is significant as the aggregation of these proteins advances neurodegeneration. Tau proteins become hyperphosphorylated in response disrupting cellular transport and further promoting Alzheimer's disease progression.
Pyroglutamate beta amyloid connects closely with Alzheimer's disease where its modified form accelerates plaque formation and neurodegeneration. Researchers also study its role in frontotemporal dementia another neurodegenerative disorder characterized by tau protein dysfunction. The aggregation of pyroglutamate beta amyloid interacts with other forms of amyloid beta as well as tau contributing to the pathological hallmarks of these disorders.